Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 10, 2006, Pages 1188-1193

  Gupta, A K ^a,b,c   Gover, M D ^b   Lynde, C W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

Diabetes; Itraconazole; Onychomycosis; Terbinafine

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; INSULIN; ITRACONAZOLE; METFORMIN; ORAL ANTIDIABETIC AGENT; TERBINAFINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYCOSIS; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; EPIDERMOPHYTON FLOCCOSUM; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STOMACH PAIN; TOENAIL ONYCHOMYCOSIS; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM;

ANTIFUNGAL AGENTS; DIABETES COMPLICATIONS; FEMALE; FOOT DERMATOSES; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; NAPHTHALENES; ONYCHOMYCOSIS; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; TREATMENT OUTCOME;

EID: 33750351838     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01698.x     Document Type: Article

References (15)

1. Rich P. Special patient populations: Onychomycosis in the diabetic patient. J Am Acad Dermatol 1996; 35: S10-S12.
2. Rich P. Onychomycosis and tinea pedis in patients with diabetes. J Am Acad Dermatol 2000; 43: S130-S134.
3. Gupta AK, Konnikov N, MacDonald P et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: A multicentre survey. Br J Dermatol 1998; 139: 665-671.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
5. Farkas B, Paul C, Dobozy A et al. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: A multicentre trial. Br J Dermatol 2002; 146: 254-260.
6. Gupta AK, Jain HC, Lynde CW, MacDonald P, Cooper EA, Summerbell RC. Prevalence and epidemiology of onychomycosis in patients visiting physicians'offices: A multicenter canadian survey of 15 000 patients. J Am Acad Dermatol 2000; 43: 244-248.
7. Kejda J. Itraconazole pulse therapy vs. continuous terbinafine dosing for toenail onychomycosis. Postgrad Med 1999: Spec No: 12-15.
8. Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol 2001; 44: 479-484.
9. Farkas B, Paul C, Dobozy A et al. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: A multicentre trial. Br J Dermatol 2002; 146: 254-260.
10. Girardin E, Vial T, Pham E, Evreux JC. [Hypoglycemia induced by oral hypoglycemic agents. Records of the French Regional Pharmacovigilance Centers 1985-1990]. Ann Med Interne (Paris) 1992; 143: 11-17.
11. USP DI -Drug Information for the Health Care Professional. Thomson MICROMEDEX, CO: Greenwood Village, 2004: 841-843.
12. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance. Clin Pharmacokinet 2000; 38: 111-180.
13. Verspeelt J, Marynissen G, Gupta AK, De Doncker P. Safety of itraconazole in diabetic patients. Dermatology 1999; 198: 382-384.
14. Albreski DA, Gross EG. The safety of itraconazole in the diabetic population. J Am Podiatr Med Assoc 1999; 89: 339-345.
15. Vickers AE, Sinclair JR, Zollinger M et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 1999; 27: 1029-1038.